SCTX (Scribe Therapeutics) NonCurrent Deferred Liabilities: $11.70 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics NonCurrent Deferred Liabilities?

Scribe Therapeutics SCTX -13.40% 8 NonCurrent Deferred Liabilities is $11.70 Mil as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Scribe Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $11.70 Mil.

Scribe Therapeutics NonCurrent Deferred Liabilities Related Terms

Scribe Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics NonCurrent Deferred Liabilities Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
NonCurrent Deferred Liabilities
49.01 19.94

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
NonCurrent Deferred Liabilities 49.01 0.00 19.94 11.70
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $11.70 Mil mean?
Scribe Therapeutics (SCTX) has a NonCurrent Deferred Liabilities of $11.70 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' NonCurrent Deferred Liabilities too high?
Scribe Therapeutics' current NonCurrent Deferred Liabilities is $11.70 Mil. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' NonCurrent Deferred Liabilities compare to ?
Scribe Therapeutics' NonCurrent Deferred Liabilities of $11.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current NonCurrent Deferred Liabilities is $11.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current NonCurrent Deferred Liabilities of $11.70 Mil. The current NonCurrent Deferred Liabilities is $11.70 Mil. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current NonCurrent Deferred Liabilities is $11.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price